[Home ] [Archive]   [ فارسی ]  
:: Main About Current Issue Archive Search Submit Contact ::
:: Volume 20, Issue 2 (6-2018) ::
J Shahrekord Univ Med Sci 2018, 20(2): 109-118 Back to browse issues page
Use of non-genetic biomarkers including anti-GAD65, anti-Insulin (II) and C-peptide in differentiating MODY type diabetes in a population of diabetic patients in Isfahan province
Akram Sarmadi , Mohammad Amin Tabatabiefar , Fatemeh Tabatabaei , Azadeh Gholizadeh , Morteza Hashemzade Chaleshtori
Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran , mchalesh@yahoo.com
Abstract:   (28 Views)
Background and aims: Diabetes mellitus is a group of metabolic disorders in the body, accompanied with increasing blood sugar levels. Diabetes is classified into 3 groups: Type 1 (T1DM), Type 2 (T2DM) and monogenic diabetes. Maturity-onset diabetes of the young (MODY) is a monogenic diabetes that is frequently mistaken for T1D or T2D. The aim of this study was to diagnose MODY using non-genetic biomarkers and determine its frequency in the population of Isfahan province. This, in addition to saving time and cost, is important for prognosis and appropriate treatment.
Methods: In this analytical descriptive study 2085 diabetic patients with a 2-6 years of disease were examined and after assessing the clinical symptoms, in 57 cases with clinical symptoms for MODY, three markers (C-peptide, anti-GAD65 and anti-insulin (II)) were measured by ELISA method and compared with healthy cases and confirmed T1D and T2D patients.
Results: In this analytical descriptive study, among 2085 diabetic patients, in 500 cases of them, the incidence of the disease was before the age of 25 years of old and after measuring 3 mentioned biochemical markers, 41 cases were negative for anti-GAD65 and anti-Insulin and had detectable C-peptide level and the differences in the levels of these three markers in suspected MODY group were meaningful (P<0.001 for anti-GAD65, P<0.017 for anti-Insulin (II) and P<0.009 for C-peptide).
Conclusion: The use of proprietary non-genetic biomarkers is very valuable for MODY detection and could be used alongside other clinical features to screen a large number of patients with diabetes. Ultimately, only suspect cases must be selected for genetic tests.
Keywords: MODY, Anti-GAD65, Anti Insulin (II), C-peptide.
Full-Text [PDF 884 kb]   (10 Downloads)    
Type of Study: Research | Subject: internal medicie
Received: 2017/07/25 | Accepted: 2017/11/1 | Published: 2018/06/13
Send email to the article author

Add your comments about this article
Your username or Email:

Write the security code in the box >


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sarmadi A, Tabatabiefar M A, Tabatabaei F, Gholizadeh A, Hashemzade Chaleshtori M. Use of non-genetic biomarkers including anti-GAD65, anti-Insulin (II) and C-peptide in differentiating MODY type diabetes in a population of diabetic patients in Isfahan province. J Shahrekord Univ Med Sci. 2018; 20 (2) :109-118
URL: http://journal.skums.ac.ir/article-1-3453-en.html


Volume 20, Issue 2 (6-2018) Back to browse issues page
مجله دانشگاه علوم پزشکی شهرکرد Journal of Shahrekord University of Medical Sciences
Persian site map - English site map - Created in 0.07 seconds with 31 queries by YEKTAWEB 3701